Investigating Patient Satisfaction With Oral Anti-Cancer Treatment
NCT ID: NCT02247583
Last Updated: 2014-09-25
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
90 participants
OBSERVATIONAL
2011-02-28
2013-07-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
The main objective of this study is to evaluate the patient perspective in the treatment of advanced renal cell carcinoma with an oral anti-cancer drug.
The following aspects will be investigated:
* Intrinsic desire for information about treatment.
* Patient satisfaction with treatment information.
* Patient satisfaction with treatment.
* Medication adherence.
* Health-related quality of life.
* The role of different health care professionals in the treatment of RCC with oral drugs
This study should reveal information necessary for the development of pharmacotherapeutic care concepts that meet the needs of cancer patients treated with an oral anti-cancer drug over a long period.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Treatment Patterns and Clinical Outcomes Among Patients With Advanced Renal Cell Carcinoma (aRCC) Receiving Systemic First-line (1st Line) Anti-cancer Treatment Under Daily Routine in Germany: Retrospective Medical Chart Review (RENALISTIC Study).
NCT05534789
A Trial to Evaluate the Characteristics of Patients Treated for Advanced Renal Cell Carcinoma With Nexavar ®
NCT00771147
Study Of AG-013736 In Patients With Refractory Metastatic Renal Cell Cancer
NCT00282048
A Phase I/II Study to Assess the Safety and Efficacy of TKI258 for the Treatment of Refractory Advanced/Metastatic Renal Cell Cancer
NCT00715182
Study to Observe Safety and Efficacy of Nexavar in Treatment of Kidney Cancer
NCT01353794
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
mRCC patients
Patients with metastatic renal cell carcinoma
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Flemish League Against Cancer
OTHER
Pfizer
INDUSTRY
Novartis
INDUSTRY
GlaxoSmithKline
INDUSTRY
KU Leuven
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Sandra De Coster
Pharmacist
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Veerle Foulon, Professor
Role: STUDY_DIRECTOR
Katholieke Universiteit Leuven - Klinische Farmacologie en Farmacotherapie
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Katholieke Universiteit Leuven - Klinische Farmacologie en Farmacotherapie
Leuven, , Belgium
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
s52586
Identifier Type: REGISTRY
Identifier Source: secondary_id
VF/2010/03
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.